RTP Mobile Logo
Meet The Professor: Management of BRAF-Mutant Melanoma — Part 2 of a 2-Part Series (Webinar Video Proceedings)
Released January 2022

Featuring perspectives from Dr Jason Luke. Published January 18, 2022. (Webinar Video Proceedings)

CE Disclosures and Faculty Information

    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of melanoma.


    • Identify patients after surgical removal of primary BRAF-mutant melanoma for whom adjuvant therapy should be considered, and counsel them about the risks and potential benefits of various systemic approaches.
    • Consider patient age, performance status and other disease-related factors in the selection of first- and later-line therapy for BRAF-mutant metastatic melanoma.
    • Use available clinical trial evidence to safely and effectively incorporate targeted, immunotherapeutic or combination therapy into the management of metastatic melanoma with a BRAF tumor mutation.
    • Identify adverse events associated with targeted therapies, immune checkpoint inhibitors and combination approaches for melanoma, and offer supportive strategies to minimize and manage side effects.
    • Recall available and emerging data with investigational strategies for BRAF-mutant melanoma, and where applicable, refer eligible patients for trial participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Jason J Luke, MD
    Director of the Cancer Immunotherapeutics Center
    UPMC Hillman Cancer Center
    Associate Professor of Medicine
    University of Pittsburgh
    Pittsburgh, Pennsylvania

    Advisory Committee: 7 Hills Pharma LLC, AbbVie Inc, Actym Therapeutics, Alphamab Oncology, Arch Oncology, F-star Therapeutics, Inzen Therapeutics, Kanaph Therapeutics, Onc.AI, Pyxis Oncology, RefleXion, Tempest Therapeutics, Xilio Therapeutics; Consulting Agreements: AbbVie Inc, Alnylam Pharmaceuticals Inc, Avillion LLP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Checkmate Pharmaceuticals, Codiak BioSciences, CrownBio, Day One Biopharmaceuticals, Eisai Inc, EMD Serono Inc, Flame Biosciences, Genentech, a member of the Roche Group, Gilead Sciences Inc, HotSpot Therapeutics, Ikena Oncology, Immunocore, Incyte Corporation, Janssen Biotech Inc, Kadmon, KSQ Therapeutics, MacroGenics Inc, Merck, Mersana Therapeutics Inc, Nektar, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Ribon Therapeutics, Rubius Therapeutics, Silicon Therapeutics, Synlogic, Synthekine, TRex Bio, Werewolf Therapeutics, Xencor; Contracted Research: AbbVie Inc, Agios Pharmaceuticals Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Corvus Pharmaceuticals, Day One Biopharmaceuticals, EMD Serono Inc, F-star Therapeutics, Genmab, Ikena Oncology, Immatics, Incyte Corporation, Kadmon, KAHR, MacroGenics Inc, Merck, Moderna, Nektar, NextCure, Numab, Pfizer Inc, Replimmune, Rubius Therapeutics, Scholar Rock, Synlogic, Takeda Pharmaceuticals USA Inc, Tizona Therapeutics Inc, Trishula Therapeutics Inc, Xencor; Data and Safety Monitoring Board/Committee: AbbVie Inc, Immutep; Ownership Interest: Actym Therapeutics, Alphamab Oncology, Arch Oncology, Kanaph Therapeutics, Onc.AI, Pyxis Oncology, Tempest Therapeutics.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    These activities are supported by educational grants from Novartis and Pfizer Inc.

    Release date: January 2022
    Expiration date: January 2023

Acknowledge and close

Watch video
(WIFI is recommended for best performance):